FMP
Entasis Therapeutics Holdings Inc.
ETTX
NASDAQ
Inactive Equity
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
2.19 USD
-0.00999999 (-0.457%)
2021
2020
2019
2018
0
0
7M
5M
0
0
0
0
0
0
7M
5M
52.32M
50.67M
51.64M
37.87M
37.1M
41.02M
40.17M
33.05M
15.21M
13.21M
13.77M
10.16M
0
0
0
0
15.21M
13.21M
13.77M
10.16M
0
-3.56M
-2.3M
-5.34M
-47.14M
-54.23M
-46.94M
-38.21M
0
3.73M
3.76M
5.73M
-47.14M
-50.5M
-43.17M
-32.48M
0
3.73M
677k
472k
-47.14M
-50.5M
-43.85M
-32.95M
-1
-2.1
-3.33
-9.64
-1
-2.1
-3.33
-9.64
47.31M
24.06M
13.16M
3.42M
47.31M
24.06M
13.16M
3.42M
-47.04M
-50.35M
-43.03M
-32.32M
2021
2020
2019
2018
-184.46M
-133.96M
-90.11M
-57.17M
-47.14M
-50.5M
-43.85M
-32.95M
0
0
0
0
0
0
0
0
-231.6M
-184.46M
-133.96M
-90.11M
-47.14M
-50.5M
-43.85M
-32.94M
2021
2020
2019
2018
802k
1.36M
1.97M
419k
104k
141k
142k
164k
-70k
-18k
-105k
-370k
768k
1.24M
1.93M
625k
2021
2020
2019
2018
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.